Integrating HEOR and Payer Considerations in Clinical Trial Design to Improve Access

Thursday, February 26, 2026

Getting FDA approval is a critical milestone, but it does not guarantee that patients will be able to access a therapy. Clinical trial design for market access is becoming increasingly important as payers place growing pressure on manufacturers to demonstrate value beyond clinical outcomes, including real-world relevance, economic impact, and clear differentiation from existing treatment options.

Christine Molbury, Jessica Duchen, and Anna Hundt Golden have a practical discussion on how market access and HEOR considerations can be built into clinical trial strategy earlier in development. They share perspectives on how payer expectations are evolving, where evidence gaps commonly emerge, and how cross-functional alignment can help avoid access challenges later in the product lifecycle.

Key Takeaways:

• FDA approval is only the first hurdle in the US market. Payers increasingly expect evidence that demonstrates real-world relevance, economic value, and differentiation versus standard of care.
• Our market access experts will explore how HEOR and payer considerations should be integrated into clinical trial design.
• Attendees will leave with practical insights to reduce downstream access risk and strengthen coverage outcomes.

Why Watch:
Whether you are responsible for clinical development, value and evidence strategy, or commercialization planning, this webinar will provide actionable insights to help strengthen access outcomes.